4 days ago · Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

3 days ago · The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.

Jul 30, 2024 · Eisai and Biogen presented LEQEMBI findings from the Clarity AD Phase 3 study, showing significant reductions in cognitive decline and functional improvements.

Mar 15, 2022 · CAMBRIDGE, Mass., and TOKYO, March 14, 2022: Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today that the companies have amended their …

Oct 23, 2017 · Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen's investigational anti-amyloid beta (Aβ) antibody for patients with Alzheimer's disease (“AD”).

Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta (Aβ) antibody for patients with Alzheimer’s disease (“AD”).

Mar 31, 2024 · LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in patients with mild cognitive impairment or mild dementia stage of disease (collectively referred to as early AD).

CAMBRIDGE, Mass., and TOKYO, March 14, 2022: Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM ® (aducanumab-avwa).

Jun 24, 2021 · Eisai and Biogen are collaborating on the joint development and commercialization of AD treatments. Eisai serves as the lead in the co-development of lecanemab.

3 days ago · Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease treatment. Quiver AI Summary Eisai Co., Ltd. and Biogen Inc. announced ...